[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336569-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336569-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-common-secretomic-signature-across-epithelial-cancers-metastatic-to-the-pleura-supports-il-6-axis-therapeutic-targeting","A common secretomic signature across epithelial cancers metastatic to the pleura supports IL-6 axis therapeutic targeting","","Many cancers metastasize to the pleura, producing malignant pleural effusions that drive dyspnea and discomfort while remaining uniformly fatal and lacking therapies that extend survival. The pleural mesothelial tight junctions create a contained space that concentrates cytokines and chemokines from mesothelium, tumor cells, and infiltrating immune cells, shaping tumor and immune behavior. Using a 252-sample malignant pleural effusion panel, the study identifies a shared secretomic profile dominated by elevated IL-6 and related signals, supporting therapeutic targeting of the IL-6/IL-6R axis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-common-secretomic-signature-across-epithelial-cancers-metastatic-to-the-pleura-supports-il-6-axis-therapeutic-targeting/336569/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-common-secretomic-signature-across-epithelial-cancers-metastatic-to-the-pleura-supports-il-6-axis-therapeutic-targeting/336569.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical problem motivates this research?","Question",{"text":63,"@type":64},"Cancers that metastasize to the pleura often cause malignant pleural effusions, leading to dyspnea and discomfort. Pleural malignancies are aggressive and have no treatment shown to prolong life.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were cytokines and chemokines measured in the study?",{"text":68,"@type":64},"The study quantified cytokine/chemokine content in 252 malignant pleural effusion samples using a 40-analyte panel with Luminex multiplexing technology.",{"name":70,"@type":61,"acceptedAnswer":71},"Which findings support targeting the IL-6/IL-6R axis?",{"text":72,"@type":64},"Eleven analytes were consistently present at high concentrations, including IL-6 and its soluble receptor component sIL-6Ra. The data indicate pleural environment signaling strongly involves IL-6 activity, motivating IL-6/IL-6R therapeutic targeting.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336569,1790531263,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TYPE Original Research PUBLISHED 24 July 2024  \nDOI 10.3389/fimmu.2024.1404373  \nOPEN ACCESS  \nEDITED BY  \nNoha Mousaad Elemam,  \nUniversity of Sharjah, United Arab Emirates  \nREVIEWED BY  \nNathaniel Richard West, Genentech Inc., United States Narjes Saheb Sharif-Askari,  \nUniversity of Sharjah, United Arab Emirates  \n*CORRESPONDENCE Albert D. Donnenberg  \n [albert.donnenberg@ahn.org](albert.donnenberg@ahn.org)[ ](albert.donnenberg@ahn.org)Vera S. Donnenberg  \n [donnenbergvs@upmc.edu](donnenbergvs@upmc.edu)  \nRECEIVED 20 March 2024  \nACCEPTED 04 July 2024  \nPUBLISHED 24 July 2024  \nCITATION  \nDonnenberg VS, Luketich JD, Popov B, Bartlett DL and Donnenberg AD (2024) A common secretomic signature across epithelial cancers metastatic to the pleura supports IL-6 axis therapeutic targeting. Front. Immunol. 15:1404373 .  \ndoi: 10.3389/fimmu.2024.1404373  \nCOPYRIGHT  \n© 2024 Donnenberg, Luketich, Popov, Bartlett and Donnenberg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nA common secretomic signature across epithelial cancers metastatic to thepleura supports IL-6 axis therapeutic targeting  \nVera S. Donnenberg 1,2,3*, James D. Luketich 1,2, Bosko Popov 2, David L. Bartlett 4,5,6 and Albert D. Donnenberg 3,4,5,7*  \n1 Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh,  \nPA, United States, 2 UPMC Hillman Cancer Centers, Pittsburgh, PA, United States, 3 McGowan Institute for Regenerative Medicine, Pittsburgh, PA, United States, 4Allegheny Health Network Cancer Institute, Pittsburgh, PA, United States, 5College of Medicine, Drexel University, Philadelphia, PA, United States, 6 Department of Surgery, College of Medicine, Drexel University, Philadelphia, PA, United States, 7 Department of Medicine, College of Medicine, Drexel University, Philadelphia, PA, United States  \nBackground: Many cancers metastasize to the pleura, resulting in effusions that cause dyspnea and discomfort. Regardless of the tissue of origin, pleural malignancies are aggressive and uniformly fatal, with no treatment shown to prolong life. The pleural mesothelial monolayer is joined by tight junctions forming a contained bioreactor-like space, concentrating cytokines and chemokines secreted by the mesothelium, tumor, and inﬁltrating immune cells. This space represents a unique environment that profoundly inﬂuences tumor and immune cell behavior. Deﬁning the pleural secretome is an important step in the rational development localized intrapleural immunotherapy.  \nMethod: We measured cytokine/chemokine content of 252 malignant pleural effusion (MPE) samples across multiple cancers using a 40-analyte panel and Luminex multiplexing technology.  \nResults: Eleven analytes were consistently present in concentrations ≥ 10. 0 pM: CXCL10/IP10 (geometric mean = 672.3 pM), CCL2/MCP1 (562.9 pM), sIL-6Ra (403.1 pM), IL-6 (137.6 pM), CXCL1/GRO (80.3 pM), TGFb1 (76.8 pM), CCL22/MDC (54.8 pM), CXCL8/IL-8 (29.2 pM), CCL11/Eotaxin (12.6 pM), IL-10 (11.3 pM), and G-CSF (11 . 0 pM) . All are capable of mediating chemotaxis, promotion of epithelial to mesenchymal transition, or immunosuppression, and many of are reportedly downstream of a pro-inﬂammatory cytokine cascade mediated by cytokine IL-6 and its soluble receptor.  \nConclusion: The data indicate high concentrations of several cytokines and chemokines across epithelial cancers metastatic to the pleura and support the contention that the pleural environment is the major factor responsible for the  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nclinical course of MPE across c","cbCaifCjYtJgsrNa","https://ap.wps.com/l/cbCaifCjYtJgsrNa","pdf",2837504,11,"English","# Background\n# Method\n# Results\n# Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What clinical problem motivates this research?\",\"answer\":\"Cancers that metastasize to the pleura often cause malignant pleural effusions, leading to dyspnea and discomfort. Pleural malignancies are aggressive and have no treatment shown to prolong life.\"},{\"question\":\"How were cytokines and chemokines measured in the study?\",\"answer\":\"The study quantified cytokine/chemokine content in 252 malignant pleural effusion samples using a 40-analyte panel with Luminex multiplexing technology.\"},{\"question\":\"Which findings support targeting the IL-6/IL-6R axis?\",\"answer\":\"Eleven analytes were consistently present at high concentrations, including IL-6 and its soluble receptor component sIL-6Ra. The data indicate pleural environment signaling strongly involves IL-6 activity, motivating IL-6/IL-6R therapeutic targeting.\"}]","A common secretomic signature across epithelial cancers metastatic to the pleura supports IL-6 axis therapeutic targeting | PDF",1790015659,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8ad94df8ed813d14ae67a2e92442d5d.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d1b193410bab17947ccca11c6f4c649.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/499d88ceebd937a62eb1406b245a246f.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ddc7019a05cfa69f936e5ed06373999.webp",980,1385]